Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
UCB, Inc. v. Accord Healthcare, Inc.
Case Number:
16-2610
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
August 24, 2018
Full Fed. Circ. Won't Rethink Upholding UCB's Vimpat Patent
The full Federal Circuit on Friday shot down a request by multiple generic-drug makers to reconsider a panel's split decision upholding the validity of a UCB Inc. patent covering the epilepsy drug Vimpat.
-
July 20, 2018
Full Fed. Circ. Should Nix UCB's Vimpat Patent, Accord Says
Generic-drug makers Accord Healthcare Inc. and Intas Pharmaceuticals Ltd. on Thursday urged the full Federal Circuit to consider invalidating a UCB Inc. patent covering the epilepsy drug Vimpat, arguing that the court's panel relied on subjective criteria to uphold the patent instead of legally mandated objectivity.
-
May 23, 2018
UCB's Epilepsy Drug Patent Win Upheld By Fed. Circ.
The Federal Circuit on Wednesday affirmed a Delaware federal court's finding that a UCB Inc. patent on the epilepsy drug Vimpat is not invalid for double patenting or obviousness, upholding the company's win over a slew of generics makers including Mylan and Accord.
-
August 08, 2017
Generic Giants Ask Fed. Circ. To Nix Vimpat Patent
Actavis Inc., Mylan Pharmaceuticals Inc. and other drug companies teamed up Tuesday for an assault on UCB Inc.'s patent for the anti-convulsant Vimpat at the Federal Circuit, seeking the chance to market generic versions of the epilepsy treatment.